Abbott Laboratories annual revenue
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Abbott Laboratories Revenue Growth & History (ABT)
Abbott Laboratories reported $44.33B in revenue for fiscal 2025, an increase of 5.67% from the previous fiscal year.
View full Abbott Laboratories company overviewAbbott Laboratories annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $44.33B | $2.38B | +5.67% |
| 2024 | 2024-12-31 | $41.95B | $1.84B | +4.59% |
| 2023 | 2023-12-31 | $40.11B | −$3.54B | −8.12% |
| 2022 | 2022-12-31 | $43.65B | $578.0M | +1.34% |
| 2021 | 2021-12-31 | $43.08B | $8.47B | +24.47% |
| 2020 | 2020-12-31 | $34.61B | $2.70B | +8.48% |
| 2019 | 2019-12-31 | $31.90B | $1.33B | +4.34% |
| 2018 | 2018-12-31 | $30.58B | $3.19B | +11.64% |
| 2017 | 2017-12-31 | $27.39B | $6.54B | +31.35% |
| 2016 | 2016-12-31 | $20.85B | $448.0M | +2.20% |
| 2015 | 2015-12-31 | $20.41B | $158.0M | +0.78% |
| 2014 | 2014-12-31 | $20.25B | $590.0M | +3.00% |
| 2013 | 2013-12-31 | $19.66B | $607.0M | +3.19% |
| 2012 | 2012-12-31 | $19.05B | −$2.36B | −11.01% |
| 2011 | 2011-12-31 | $21.41B | −$13.76B | −39.13% |
| 2010 | 2010-12-31 | $35.17B | $4.40B | +14.31% |
| 2009 | 2009-12-31 | $30.76B | $1.24B | +4.19% |
| 2008 | 2008-12-31 | $29.53B | $3.61B | +13.94% |
| 2007 | 2007-12-31 | $25.91B | — | — |
Abbott Laboratories quarterly revenue
Q1.08
Q2.08
Q3.08
Q4.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $11.16B | $806.0M | +7.78% |
| Q4 2025 | 2025-12-31 | $11.46B | $485.0M | +4.42% |
| Q3 2025 | 2025-09-30 | $11.37B | $734.0M | +6.90% |
| Q2 2025 | 2025-06-30 | $11.14B | $765.0M | +7.37% |
| Q1 2025 | 2025-03-31 | $10.36B | $394.0M | +3.95% |
| Q4 2024 | 2024-12-31 | $10.97B | $733.0M | +7.16% |
| Q3 2024 | 2024-09-30 | $10.63B | $492.0M | +4.85% |
| Q2 2024 | 2024-06-30 | $10.38B | $399.0M | +4.00% |
| Q1 2024 | 2024-03-31 | $9.96B | $217.0M | +2.23% |
| Q4 2023 | 2023-12-31 | $10.24B | $150.0M | +1.49% |
| Q3 2023 | 2023-09-30 | $10.14B | −$267.0M | −2.56% |
| Q2 2023 | 2023-06-30 | $9.98B | −$1.28B | −11.36% |
| Q1 2023 | 2023-03-31 | $9.75B | −$2.15B | −18.06% |
| Q4 2022 | 2022-12-31 | $10.09B | −$1.38B | −12.01% |
| Q3 2022 | 2022-09-30 | $10.41B | −$518.0M | −4.74% |
| Q2 2022 | 2022-06-30 | $11.26B | $1.03B | +10.11% |
| Q1 2022 | 2022-03-31 | $11.89B | $1.44B | +13.76% |
| Q4 2021 | 2021-12-31 | $11.47B | $767.0M | +7.17% |
| Q3 2021 | 2021-09-30 | $10.93B | $2.08B | +23.44% |
| Q2 2021 | 2021-06-30 | $10.22B | $2.90B | +39.51% |
| Q1 2021 | 2021-03-31 | $10.46B | $2.73B | +35.34% |
| Q4 2020 | 2020-12-31 | $10.70B | $2.39B | +28.71% |
| Q3 2020 | 2020-09-30 | $8.85B | $777.0M | +9.62% |
| Q2 2020 | 2020-06-30 | $7.33B | −$651.0M | −8.16% |
| Q1 2020 | 2020-03-31 | $7.73B | $191.0M | +2.53% |
| Q4 2019 | 2019-12-31 | $8.31B | $549.0M | +7.07% |
| Q3 2019 | 2019-09-30 | $8.08B | $420.0M | +5.49% |
| Q2 2019 | 2019-06-30 | $7.98B | $212.0M | +2.73% |
| Q1 2019 | 2019-03-31 | $7.54B | $145.0M | +1.96% |
| Q4 2018 | 2018-12-31 | $7.76B | $176.0M | +2.32% |
| Q3 2018 | 2018-09-30 | $7.66B | $827.0M | +12.11% |
| Q2 2018 | 2018-06-30 | $7.77B | $1.13B | +17.03% |
| Q1 2018 | 2018-03-31 | $7.39B | $1.05B | +16.65% |
| Q4 2017 | 2017-12-31 | $7.59B | $2.26B | +42.30% |
| Q3 2017 | 2017-09-30 | $6.83B | $1.53B | +28.80% |
| Q2 2017 | 2017-06-30 | $6.64B | $1.30B | +24.45% |
| Q1 2017 | 2017-03-31 | $6.33B | $1.45B | +29.68% |
| Q4 2016 | 2016-12-31 | $5.33B | $145.0M | +2.79% |
| Q3 2016 | 2016-09-30 | $5.30B | $152.0M | +2.95% |
| Q2 2016 | 2016-06-30 | $5.33B | $163.0M | +3.15% |
| Q1 2016 | 2016-03-31 | $4.88B | −$12.0M | −0.25% |
| Q4 2015 | 2015-12-31 | $5.19B | −$168.0M | −3.14% |
| Q3 2015 | 2015-09-30 | $5.15B | $71.0M | +1.40% |
| Q2 2015 | 2015-06-30 | $5.17B | $113.0M | +2.23% |
| Q1 2015 | 2015-03-31 | $4.90B | $142.0M | +2.99% |
| Q4 2014 | 2014-12-31 | $5.36B | $284.0M | +5.60% |
| Q3 2014 | 2014-09-30 | $5.08B | $274.0M | +5.70% |
| Q2 2014 | 2014-06-30 | $5.06B | $124.0M | +2.51% |
| Q1 2014 | 2014-03-31 | $4.75B | −$92.0M | −1.90% |
| Q4 2013 | 2013-12-31 | $5.07B | −$560.0M | −9.94% |
| Q3 2013 | 2013-09-30 | $4.80B | −$460.0M | −8.74% |
| Q2 2013 | 2013-06-30 | $4.93B | −$380.0M | −7.15% |
| Q1 2013 | 2013-03-31 | $4.85B | −$437.0M | −8.27% |
| Q4 2012 | 2012-12-31 | $5.63B | −$4.75B | −45.73% |
| Q3 2012 | 2012-09-30 | $5.26B | −$4.55B | −46.37% |
| Q2 2012 | 2012-06-30 | $5.31B | −$4.30B | −44.75% |
| Q1 2012 | 2012-03-31 | $5.28B | −$3.76B | −41.55% |
| Q4 2011 | 2011-12-31 | $10.38B | $409.6M | +4.11% |
| Q3 2011 | 2011-09-30 | $9.82B | $1.14B | +13.17% |
| Q2 2011 | 2011-06-30 | $9.62B | $790.3M | +8.95% |
| Q1 2011 | 2011-03-31 | $9.04B | $1.34B | +17.44% |
| Q4 2010 | 2010-12-31 | $9.97B | $1.18B | +13.40% |
| Q3 2010 | 2010-09-30 | $8.67B | $913.2M | +11.77% |
| Q2 2010 | 2010-06-30 | $8.83B | $1.33B | +17.76% |
| Q1 2010 | 2010-03-31 | $7.70B | $980.0M | +14.59% |
| Q4 2009 | 2009-12-31 | $8.79B | $839.8M | +10.56% |
| Q3 2009 | 2009-09-30 | $7.76B | $263.6M | +3.52% |
| Q2 2009 | 2009-06-30 | $7.49B | $180.9M | +2.47% |
| Q1 2009 | 2009-03-31 | $6.72B | −$47.2M | −0.70% |
| Q4 2008 | 2008-12-31 | $7.95B | — | — |
| Q3 2008 | 2008-09-30 | $7.50B | — | — |
| Q2 2008 | 2008-06-30 | $7.31B | — | — |
| Q1 2008 | 2008-03-31 | $6.77B | — | — |
Abbott Laboratories revenue growth trends
Over the last five reported fiscal years, revenue grew from $34.61B to $44.33B, a compound annual growth rate of 5.08%. Abbott Laboratories's latest reported quarter, Q1 2026, generated $11.16B in revenue, an increase of 7.78% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Abbott Laboratories source filings ↗Community posts
Abbott launches blood-based colorectal cancer screening test in the US
Abbott ($ABT) has launched SimpleScreen CRC in the United States, adding an FDA-approved blood test to its colorectal cancer screening portfolio. Freenome develops and manufactures the test, while Abbott holds exclusive commercialization ri ...
Abbott agrees to $385 million settlement over infant-formula recall claims
Abbott ($ABT) said it will pay $385 million to resolve a previously disclosed Justice Department investigation and lawsuit, together with claims brought by certain whistleblowers and state attorneys general. The matters concern manufacturin ...
